Medicines and Healthcare products Regulatory Agency Sustainability Profile
The Medicines and Healthcare products Regulatory Agency (MHRA), headquartered in Great Britain, plays a pivotal role in the regulation of medicines and healthcare products. Established in 2003, the agency has evolved to ensure the safety, efficacy, and quality of pharmaceuticals and medical devices across the UK. Operating primarily within the healthcare and pharmaceutical industries, the MHRA oversees a wide range of services, including the approval of new medicines, monitoring of drug safety, and regulation of clinical trials. Its unique position as a regulatory authority allows it to maintain high standards that protect public health. With notable achievements in streamlining the approval process for innovative therapies, the MHRA is recognised for its commitment to fostering a safe healthcare environment. Its influence extends beyond the UK, contributing to global regulatory discussions and initiatives.
DitchCarbon Score
How does Medicines and Healthcare products Regulatory Agency's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medicines and Healthcare products Regulatory Agency's score of 26 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medicines and Healthcare products Regulatory Agency's reported carbon emissions
In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) reported total carbon emissions of approximately 7,600,000 kg CO2e. This figure includes 5,000,000 kg CO2e from Scope 1 emissions, 2,000,000 kg CO2e from Scope 2 emissions (purchased electricity), and 600,000 kg CO2e from Scope 3 emissions. In 2024, the agency's emissions were similar, with 5,000,000 kg CO2e from Scope 1, a negative Scope 2 figure of -2,200,000 kg CO2e (indicating a potential reduction or offset), and 500,000 kg CO2e from Scope 3. The 2023 data is not available, and prior years show a consistent pattern of emissions, with 2022 emissions at 5,000,000 kg CO2e (Scope 1), 1,500,000 kg CO2e (Scope 2), and 300,000 kg CO2e (Scope 3). Despite the significant emissions, the MHRA has not set specific reduction targets or initiatives as part of the Science Based Targets initiative (SBTi) or other climate pledges. The agency's commitment to reducing its carbon footprint remains unspecified, indicating a potential area for future development in climate strategy. Overall, the MHRA's emissions data reflects a substantial environmental impact, with opportunities for improvement in sustainability practices and emissions reduction commitments.
How Carbon Intensive is Medicines and Healthcare products Regulatory Agency's Industry?
How Carbon Intensive is Medicines and Healthcare products Regulatory Agency's Location?
Medicines and Healthcare products Regulatory Agency's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medicines and Healthcare products Regulatory Agency has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
